VYNE Therapeutics (VYNE) Revenue (2016 - 2026)
VYNE Therapeutics (VYNE) posted Revenue of $86000.0 for Q1 2026, down 14.0% on a QoQ basis from $100000.0 in Q2 2025, and down 57.0% year-over-year from $200000.0 in Q1 2025.
VYNE Therapeutics (VYNE) Revenue (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Revenue history runs 11 years deep, the most recent figure standing at $86000.0 for Q1 2026.
- Quarterly Revenue fell 57.0% year-over-year to $86000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $469000.0 (down 22.09% YoY) and the FY2025 annual result came in at $570000.0, up 14.0% from the prior year.
- Revenue was $86000.0 for Q1 2026 at VYNE Therapeutics, down from $100000.0 in the prior quarter.
- Across five years, Revenue topped out at $200000.0 in Q1 2025 and bottomed at $29000.0 in Q4 2022.
- A 5-year average of $118533.3 and a median of $100000.0 in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue slumped 89.38% — and 2023, when it surged 162.07%.
- VYNE Therapeutics' Revenue stood at $29000.0 in 2022, then jumped by 162.07% to $76000.0 in 2023, then grew by 9.21% to $83000.0 in 2024, then rose by 20.48% to $100000.0 in 2025, then dropped by 14.0% to $86000.0 in 2026.
- Business Quant data shows VYNE's Revenue at $86000.0 in Q1 2026, $100000.0 in Q2 2025, and $200000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1.17 Bn |
| 10 | VYNE Therapeutics | 1.08 Bn | 1.05 Bn | - | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 198,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Sep 30, 2023 | 114,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | 126,000.00 |
| Mar 31, 2022 | 178,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Sep 30, 2021 | 133,000.00 |
| Jun 30, 2021 | 295,000.00 |
| Mar 31, 2021 | 230,000.00 |
| Dec 31, 2020 | 4.29 Mn |